Durai Sundar

Durai Sundar is an Indian computational biologist, bioinformatician and the current Head of the Department of Biochemical Engineering and Biotechnology at the Indian Institute of Technology, Delhi. He is known for his studies in the fields of genome editing tool designing, biological studies of natural drugs and metabolic engineering as well as for his participation in the Indo-Japanese collaborative research initiatives on anti-cancer drug development and is a life member of the National Academy of Sciences, India.

The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2012. Provided by Wikipedia
Showing 1 - 20 results of 34 for search 'Durai Sundar', query time: 0.06s Refine Results
  1. 1
    SurvCNN: A Discrete Time-to-Event Cancer Survival Estimation Framework Using Image Representations of Omics Data

    SurvCNN: A Discrete Time-to-Event Cancer Survival Estimation Framework Using Image Representations of Omics Data by Yogesh Kalakoti, Shashank Yadav, Durai Sundar

    Published 2021-06-01
    Get full text
    Article
  2. 2
    Biosurfactants: Potential Agents for Controlling Cellular Communication, Motility, and Antagonism

    Biosurfactants: Potential Agents for Controlling Cellular Communication, Motility, and Antagonism by Jyoti Sharma, Durai Sundar, Preeti Srivastava

    Published 2021-10-01
    Get full text
    Article
  3. 3
    Deep Neural Network-Assisted Drug Recommendation Systems for Identifying Potential Drug–Target Interactions

    Deep Neural Network-Assisted Drug Recommendation Systems for Identifying Potential Drug–Target Interactions by Yogesh Kalakoti, Shashank Yadav, Durai Sundar

    Published 2022-03-01
    Get full text
    Article
  4. 4
    Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

    Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer by Vidhi Malik, Yogesh Kalakoti, Durai Sundar

    Published 2021-03-01
    Get full text
    Article
  5. 5
    A Machine Learning Approach to Identify the Importance of Novel Features for CRISPR/Cas9 Activity Prediction

    A Machine Learning Approach to Identify the Importance of Novel Features for CRISPR/Cas9 Activity Prediction by Dhvani Sandip Vora, Yugesh Verma, Durai Sundar

    Published 2022-08-01
    Get full text
    Article
  6. 6
    Hybrid Multitask Learning Reveals Sequence Features Driving Specificity in the CRISPR/Cas9 System

    Hybrid Multitask Learning Reveals Sequence Features Driving Specificity in the CRISPR/Cas9 System by Dhvani Sandip Vora, Shashank Yadav, Durai Sundar

    Published 2023-04-01
    Get full text
    Article
  7. 7
    Improved Machine Learning-Based Model for the Classification of Off-Targets in the CRISPR/Cpf1 System

    Improved Machine Learning-Based Model for the Classification of Off-Targets in the CRISPR/Cpf1 System by Pragya Kesarwani, Dhvani Sandip Vora, Durai Sundar

    Published 2023-11-01
    Get full text
    Article
  8. 8
    The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.

    The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside... by Shantanu Shukla, Khushboo Bafna, Durai Sundar, Sunil S Thorat

    Published 2014-01-01
    Get full text
    Article
  9. 9
    Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity

    Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity by Vipul Kumar, Jasdeep Singh, Seyed E. Hasnain, Durai Sundar

    Published 2021-08-01
    Get full text
    Article
  10. 10
    A systematic comparison of human mitochondrial genome assembly tools

    A systematic comparison of human mitochondrial genome assembly tools by Nirmal Singh Mahar, Rohit Satyam, Durai Sundar, Ishaan Gupta

    Published 2023-09-01
    Get full text
    Article
  11. 11
    Phosphatidylserine Exposed Lipid Bilayer Models for Understanding Cancer Cell Selectivity of Natural Compounds: A Molecular Dynamics Simulation Study

    Phosphatidylserine Exposed Lipid Bilayer Models for Understanding Cancer Cell Selectivity of Natural Compounds: A Molecular Dynamics Simulation Study by Navaneethan Radhakrishnan, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

    Published 2022-01-01
    Get full text
    Article
  12. 12
    Mixed Inhibition of cPEPCK by Genistein, Using an Extended Binding Site Located Adjacent to Its Catalytic Cleft.

    Mixed Inhibition of cPEPCK by Genistein, Using an Extended Binding Site Located Adjacent to Its Catalytic Cleft. by Shashank Prakash Katiyar, Arpit Jain, Jaspreet Kaur Dhanjal, Durai Sundar

    Published 2015-01-01
    Get full text
    Article
  13. 13
    Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study

    Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study by Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

    Published 2021-01-01
    Get full text
    Article
  14. 14
    Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers

    Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers by Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

    Published 2021-01-01
    Get full text
    Article
  15. 15
    Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone

    Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone by Vidhi Malik, Navaneethan Radhakrishnan, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

    Published 2022-01-01
    Get full text
    Article
  16. 16
    Computational Structure-Based De Novo Design of Hypothetical Inhibitors against the Anti- Inflammatory Target COX-2.

    Computational Structure-Based De Novo Design of Hypothetical Inhibitors against the Anti- Inflammatory Target COX-2. by Jaspreet Kaur Dhanjal, Anith Kumar Sreenidhi, Khushboo Bafna, Shashank Prakash Katiyar, Sukriti Goyal, Abhinav Grover, Durai Sundar

    Published 2015-01-01
    Get full text
    Article
  17. 17
    The complete chloroplast genome of Dendrobium nobile, an endangered medicinal orchid from north-east India and its comparison with related Dendrobium species

    The complete chloroplast genome of Dendrobium nobile, an endangered medicinal orchid from north-east India and its comparison with related Dendrobium species by Ruchishree Konhar, Manish Debnath, Santosh Vishwakarma, Atanu Bhattacharjee, Durai Sundar, Pramod Tandon, Debasis Dash, Devendra Kumar Biswal

    Published 2019-11-01
    Get full text
    Article
  18. 18
    Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers

    Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers by Jayarani F. Putri, Priyanshu Bhargava, Jaspreet Kaur Dhanjal, Tomoko Yaguchi, Durai Sundar, Sunil C. Kaul, Renu Wadhwa

    Published 2019-12-01
    Get full text
    Article
  19. 19
    Identification and Characterization of Mortaparib<sup>Plus</sup>—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms

    Identification and Characterization of Mortaparib<sup>Plus</sup>—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Ty... by Anissa Nofita Sari, Ahmed Elwakeel, Jaspreet Kaur Dhanjal, Vipul Kumar, Durai Sundar, Sunil C. Kaul, Renu Wadhwa

    Published 2021-02-01
    Get full text
    Article
  20. 20
    Mutant p53<sup>L194F</sup> Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib<sup>Plus</sup>, a Multimodal Small Molecule Inhibitor

    Mutant p53<sup>L194F</sup> Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib<sup>Plus</sup>, a Multimodal Small Mo... by Ahmed Elwakeel, Anissa Nofita Sari, Jaspreet Kaur Dhanjal, Hazna Noor Meidinna, Durai Sundar, Sunil C. Kaul, Renu Wadhwa

    Published 2021-06-01
    Get full text
    Article

Search Tools: